nach oben

Diabetologia

Erschienen in:

01.04.2013 | Article

The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study

verfasst von: C. Lorenzo, A. J. Hanley, M. J. Rewers, S. M. Haffner

Erschienen in: Diabetologia | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Markers of liver injury, such as alanine aminotransferase (ALT), have been associated with atherogenic lipoprotein changes. We examined the extent to which this association was explained by insulin resistance, adiposity, glucose tolerance and chronic inflammation.

Methods

In this analysis we included 824 non-diabetic participants (age 40–69 years) in the Insulin Resistance Atherosclerosis Study. No participants reported excessive alcohol intake or treatment with lipid-lowering medications. Lipoproteins and apolipoproteins were measured by conventional methods and lipoprotein heterogeneity by nuclear magnetic resonance (NMR) spectroscopy.

Results

ALT had a positive relationship with triacylglycerols, LDL-to-HDL-cholesterol ratio and apolipoprotein B (ApoB) after adjusting for demographic variables (p < 0.001 for all three relationships). ALT was also associated with the following NMR lipoproteins: positively with large VLDL (p < 0.001), intermediate-density lipoprotein (IDL) (p < 0.001) and small LDL subclass particles (p < 0.001), and VLDL particle size (p < 0.001); and negatively with large LDL subclass particles (p < 0.05) and LDL (p < 0.001) and HDL particle sizes (p < 0.01). ALT remained associated with IDL and small LDL subclass particles and ApoB after adjusting for glucose tolerance, adiposity, directly measured insulin sensitivity and C-reactive protein.

Conclusions/interpretation

ALT is associated with a wide range of atherogenic lipoprotein changes, which are partially explained by insulin resistance, adiposity, glucose tolerance and chronic inflammation. Because of the significant variability in the relationship between ALT and liver fat, further studies are needed to assess the extent of the lipoprotein changes using a direct measure of liver fat.

Xu J, Kochanek KD, Murphy SL, Tejada-Vera B (2010) Deaths: final data for 2007. Natl Vital Stat Rep 58:19

Younossi ZM, Stepanova M, Afendy M et al (2011) Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9:524–530PubMedCrossRef

Mulhall BP, Ong JP, Younossi ZM (2002) Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 17:1136–1143PubMedCrossRef

Schindhelm RK, Dekker JM, Nijpels G et al (2007) Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191:391–396PubMedCrossRef

Ford I, Mooijaart SP, Lloyd S et al (2011) The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol 40:1530–1538PubMedCrossRef

Lazo M, Hernaez R, Bonekamp S et al (2011) Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 343:d6891PubMedCrossRef

Hanley AJ, Williams K, Festa A et al (2004) Elevations in markers of liver injury and risk of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 53:2623–2632PubMedCrossRef

Lee DH, Ha MH, Kim JH et al (2003) Gamma-glutamyltransferase and diabetes—a 4 year follow-up study. Diabetologia 46:359–364PubMedCrossRef

Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM (2005) Liver markers and development of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Diabetes 54:3140–3147PubMedCrossRef

10.

Marchesini G, Brizi M, Bianchi G et al (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844–1850PubMedCrossRef

11.

Hanley AJ, Wagenknecht LE, Festa A, D’Agostino RB Jr, Haffner SM (2007) Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. Diabetes Care 30:1819–1827PubMedCrossRef

12.

Adiels M, Taskinen MR, Packard C et al (2006) Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755–765PubMedCrossRef

13.

Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC (2003) Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285:E906–E916PubMed

14.

Kotronen A, Yki-Järvinen H, Sevastianova K et al (2011) Comparison of the relative contributions of intra-abdominal and liver fat to components of the metabolic syndrome. Obesity (Silver Spring) 19:23–28CrossRef

15.

Burgert TS, Taksali SE, Dziura J et al (2006) Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab 91:4287–4294PubMedCrossRef

16.

McKimmie RL, Daniel KR, Carr JJ et al (2008) Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 103:3029–3035PubMedCrossRef

17.

Bethel MA, Deedwania P, Levitt NS et al (2009) Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population. Diabet Med 26:1204–1211PubMedCrossRef

18.

Kazumi T, Kawaguchi A, Hirano T, Yoshino G (2006) Serum alanine aminotransferase is associated with serum adiponectin, C-reactive protein and apolipoprotein B in young healthy men. Horm Metab Res 38:119–124PubMedCrossRef

19.

Kelishadi R, Cook SR, Amra B, Adibi A (2009) Factors associated with insulin resistance and non-alcoholic fatty liver disease among youths. Atherosclerosis 204:538–543PubMedCrossRef

20.

Otvos JD (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48:171–180PubMed

21.

Festa A, Williams K, Hanley AJ et al (2005) Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111:3465–3472PubMedCrossRef

22.

Lyons TJ, Jenkins AJ, Zheng D et al (2006) Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabet Med 23:955–966PubMedCrossRef

23.

Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM (2009) Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119:931–939PubMedCrossRef

24.

Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM (2010) Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 59:1153–1160PubMedCrossRef

25.

Westerbacka J, Cornér A, Tiikkainen M et al (2004) Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47:1360–1369PubMedCrossRef

26.

Wagenknecht LE, Mayer EJ, Rewers M et al (1995) The insulin resistance atherosclerosis study: design, objectives and recruitment results. Ann Epidemiol 5:464–472PubMedCrossRef

27.

Pacini G, Bergman RN (1986) MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23:113–122PubMedCrossRef

28.

Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV (1997) Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Arterioscler Thromb Vasc Biol 17:64–71PubMedCrossRef

29.

D'Agostino RB Jr, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM (2004) Cardiovascular disease risk factors predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes Care 27:2234–2240PubMedCrossRef

30.

Kudoh A, Sakai T, Ishihara H, Matsuki A (1997) Increase in serum creatine phosphokinase concentrations after suxamethonium during sevoflurane or isoflurane anaesthesia in children. Br J Anaesth 78:372–374PubMedCrossRef

31.

Festa A, D’Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47PubMedCrossRef

32.

Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome—a new worldwide definition. Lancet 366:1059–1062PubMedCrossRef

33.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef

34.

Kotronen A, Peltonen M, Hakkarainen A et al (2009) Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137:865–872PubMedCrossRef

35.

Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854PubMedCrossRef

36.

Sterling RK, Lissen E, Clumeck N et al (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1325PubMedCrossRef

37.

Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM et al (2002) Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023–3028PubMedCrossRef

38.

Simonen P, Kotronen A, Hallikainen M et al (2011) Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 54:153–159PubMedCrossRef

39.

Fabbrini E, Magkos F, Mohammed BS et al (2009) Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 106:15430–15435PubMedCrossRef

40.

Nannipieri M, Gonzales C, Baldi S et al (2005) Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City Diabetes Study. Diabetes Care 28:1757–1762PubMedCrossRef

41.

Oh SY, Cho YK, Kang MS et al (2006) The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 55:1604–1609PubMedCrossRef

42.

Lazo M, Solga SF, Horska A et al (2010) Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 33:2156–2163PubMedCrossRef

43.

Després JP, Ross R, Boka G, Alméras N, Lemieux I (2009) Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 29:416–423PubMedCrossRef

44.

Walldius G, Jungner I (2005) Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 26:210–212PubMedCrossRef

45.

Brewer HB (2004) Increasing HDL cholesterol levels. N Engl J Med 350:1491–1494PubMedCrossRef

46.

D’Adamo E, Northrup V, Weiss R et al (2010) Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. Am J Clin Nutr 92:500–508PubMedCrossRef

47.

Guerrero R, Vega GL, Grundy SM, Browning JD (2009) Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 49:791–801PubMedCrossRef

48.

Vozarova B, Stefan N, Lindsay RS et al (2002) High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51:1889–1895PubMedCrossRef

49.

McPherson S, Stewart SF, Henderson E, Burt AD, Day CP (2010) Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59:1265–1269PubMedCrossRef

Titel: The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study
verfasst von: C. Lorenzo
A. J. Hanley
M. J. Rewers
S. M. Haffner
Publikationsdatum: 01.04.2013
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 4/2013
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-012-2826-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Clinical presentation of 6q24 transient neonatal diabetes mellitus (6q24 TNDM) and genotype–phenotype correlation in an international cohort of patients

Diabetes, bilirubin and amputations: is there a link?

ER stress signalling through eIF2α and CHOP, but not IRE1α, attenuates adipogenesis in mice

Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3

HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes